BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hofman P. New insights into the interaction of the immune system with non-small cell lung carcinomas. Transl Lung Cancer Res 2020;9:2199-213. [PMID: 33209644 DOI: 10.21037/tlcr-20-178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lee SM, Lee JW, Lee J, Jo IY, Jang SJ. Prognostic Value of Dual-Time-Point [18F]FDG PET/CT for Predicting Distant Metastasis after Treatment in Patients with Non-Small Cell Lung Cancer. JPM 2022;12:592. [DOI: 10.3390/jpm12040592] [Reference Citation Analysis]
2 Hamilton G, Plangger A. The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. Biologics 2021;15:265-77. [PMID: 34262255 DOI: 10.2147/BTT.S290305] [Reference Citation Analysis]
3 Sholl LM. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Mod Pathol 2021. [PMID: 34608245 DOI: 10.1038/s41379-021-00932-5] [Reference Citation Analysis]
4 Wu G, Yan Y, Cai Y, Peng B, Li J, Huang J, Xu Z, Zhou J. ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognostic Biomarkers in Lung Adenocarcinoma Pathogenesis. Front Cell Dev Biol 2021;9:633927. [PMID: 34150745 DOI: 10.3389/fcell.2021.633927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]